| Original language | English |
|---|---|
| Pages (from-to) | 1144-1146 |
| Number of pages | 3 |
| Journal | Annals of the rheumatic diseases |
| Volume | 78 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 1 2019 |
Keywords
- ANCA-associated vasculitis
- MUC5B
- interstitial lung disease
- myeloperoxidase-ANCA
- polymorphism
ASJC Scopus subject areas
- Rheumatology
- Immunology and Allergy
- Immunology
- Biochemistry, Genetics and Molecular Biology(all)
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis. / Namba, Natsumi; Kawasaki, Aya; Sada, Kenei; Hirano, Fumio; Kobayashi, Shigeto; Yamada, Hidehiro; Furukawa, Hiroshi; Shimada, Kota; Hashimoto, Atsushi; Matsui, Toshihiro; Nagasaka, Kenji; Sugihara, Takahiko; Suzuki, Aika; Yamagata, Kunihiro; Sumida, Takayuki; Tohma, Shigeto; Homma, Sakae; Ozaki, Shoichi; Hashimoto, Hiroshi; Makino, Hirofumi; Arimura, Yoshihiro; Harigai, Masayoshi; Tsuchiya, Naoyuki.
In: Annals of the rheumatic diseases, Vol. 78, No. 8, 01.08.2019, p. 1144-1146.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis
AU - Namba, Natsumi
AU - Kawasaki, Aya
AU - Sada, Kenei
AU - Hirano, Fumio
AU - Kobayashi, Shigeto
AU - Yamada, Hidehiro
AU - Furukawa, Hiroshi
AU - Shimada, Kota
AU - Hashimoto, Atsushi
AU - Matsui, Toshihiro
AU - Nagasaka, Kenji
AU - Sugihara, Takahiko
AU - Suzuki, Aika
AU - Yamagata, Kunihiro
AU - Sumida, Takayuki
AU - Tohma, Shigeto
AU - Homma, Sakae
AU - Ozaki, Shoichi
AU - Hashimoto, Hiroshi
AU - Makino, Hirofumi
AU - Arimura, Yoshihiro
AU - Harigai, Masayoshi
AU - Tsuchiya, Naoyuki
N1 - Funding Information: Competing interests FH is employed by The Department of Lifetime Clinical Immunology of Tokyo Medical and Dental University (TMDU), which has received unrestricted research grants from Chugai Pharmaceutical Co, Ltd. Ono Pharmaceuticals; Mitsubishi Tanabe Pharma Co. UCB Japan; CSL Behring; Towa Pharmaceutical Co, Ltd. Abbvie Japan Co, Ltd. Japan Blood Products Organization; Ayumi Pharmaceutical Co; and Nippon Kayaku Co, Ltd, with which TMDU currently pays the salary of FH. FH has also received speaking fees from Ono Pharmaceuticals, Astellas Pharma Inc. Sumitomo Dainippon Pharma and Chugai Pharmaceutical Co, Ltd. KS has received lecture fee from Chugai. HF has the following conflicts, and the following funders are supported wholly or in part by the indicated pharmaceutical companies. The Japan Research Foundation for Clinical Pharmacology is run by Daiichi Sankyo, the Takeda Science Foundation is supported by an endowment from Takeda Pharmaceutical Company and the Nakatomi Foundation was established by Hisamitsu Pharmaceutical Co, Inc. The Daiwa Securities Health Foundation was established by Daiwa Securities Group Inc. and Mitsui Sumitomo Insurance Welfare Foundation was established by Mitsui Sumitomo Insurance Co, Ltd. HF was supported by research grants from Bristol-Myers Squibb Co. HF received honoraria from Ajinomoto Co, Inc., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co, Ltd. Pfizer Japan Inc, and Takeda Pharmaceutical Company, Luminex Japan Corporation Ltd, and Ayumi Pharmaceutical Corporation. ST was supported by research grants from Abbott Japan Co, Ltd, Astellas Pharma Inc, Chugai Pharmaceutical Co, Ltd. Eisai Co, Ltd, Mitsubishi Tanabe Pharma Corporation, Merck Sharp and Dohme Inc. Pfizer Japan Inc, Takeda Pharmaceutical Company Limited and Teijin Pharma Limited. TSug has received honoraria from Chugai Pharmaceutical Co, Ltd. Takeda Pharmaceutical Co. Ltd, Mitsubishi-Tanabe Pharma Co, Astellas Pharma Inc, Bristol Myers Squibb K.K. Pfizer Japan Inc, UCB Japan Co. Ltd, and Abbvie Japan Co, Ltd, and has received research grant support from Takeda Pharmaceutical Co, Ltd, Astellas Pharma Inc, and Teijin Pharma Ltd. AH has received research funding from Chugai Pharmaceutical Co, Ltd. HM is a consultant for AbbVie and Teijin, receives speaker honoraria from Boehringer-Ingelheim. MH has received research grants and/or honoraria from Abbott Japan Co, Ltd. Astellas Pharma Inc; Bristol-Myers Squibb K.K. Chugai Pharmaceutical Co, Ltd. Eisai Co, Ltd. Janssen Pharmaceutical K.K. Mitsubishi Tanabe Pharma Co; Santen Pharmaceutical Co; Ltd. Takeda Pharmaceutical Co, Ltd. Teijin Pharma, Ltd. and Pfizer Japan Inc. NT has received 2015 Japan College of Rheumatology Award from Japan College of Rheumatology and 2017 Novartis Rheumatology Award from Japan Rheumatism Association with research fundings, and speaker’s honoraria from Ayumi Pharmaceutical Corporation. Funding Information: Funding This study was supported by the grants from the Japan Agency for Medical Research and Development "The Study Group for Strategic Exploration of Drug Seeds for ANCA Associated Vasculitis and Construction of Clinical Evidence (grant number 17ek0109104h0003)”, ”The Strategic Study Group to Establish the Evidence for Intractable Vasculitis Guideline (grant number 17ek0109121h0003)” and “Multitiered study to address clinical questions for management of intractable vasculitides (grant number 18ek0109360h001)", and an award grant from Japan College of Rheumatology.
PY - 2019/8/1
Y1 - 2019/8/1
KW - ANCA-associated vasculitis
KW - MUC5B
KW - interstitial lung disease
KW - myeloperoxidase-ANCA
KW - polymorphism
UR - http://www.scopus.com/inward/record.url?scp=85061621500&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061621500&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2018-214263
DO - 10.1136/annrheumdis-2018-214263
M3 - Letter
C2 - 30765393
AN - SCOPUS:85061621500
VL - 78
SP - 1144
EP - 1146
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
SN - 0003-4967
IS - 8
ER -